ODAC Will Have Bigger Role At Avastin Hearing Than Previously Described
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells the Oncologic Drugs Advisory Committee it will have a voting role at the two-day hearing, in contrast with CDER's original expectation that the panel would provide advice and recommendations but not vote.
You may also be interested in...
US Accelerated Approval: As Makena Withdrawal Hearing Looms, A Look Back At The Avastin Experience
With the public hearing on Covis’ drug for preterm birth prevention expected in 2022, the Pink Sheet talked to several former FDA officials and advisory committee members about their experiences at the 2011 hearing on withdrawal of Avastin’s accelerated approval for breast cancer.
Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.
Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.